On Friday, Humacyte Inc (NASDAQ: HUMA) opened lower -1.65% from the last session, before settling in for the closing price of $1.21. Price fluctuations for HUMA have ranged from $1.15 to $9.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 42.00% at the time writing. With a float of $125.75 million, this company’s outstanding shares have now reached $130.03 million.
Considering the fact that the conglomerate employs 220 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of -1582.71%, and the pretax margin is -2057.29%.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Humacyte Inc is 18.94%, while institutional ownership is 28.89%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 42.00% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Check out the current performance indicators for Humacyte Inc (HUMA). In the past quarter, the stock posted a quick ratio of 2.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.30 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Compared to the last year’s volume of 3.31 million, its volume of 2.6 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 6.40%. Additionally, its Average True Range was 0.14.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 0.71%, which indicates a significant decrease from 2.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.41% in the past 14 days, which was lower than the 121.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0562, while its 200-day Moving Average is $4.4692. Nevertheless, the first resistance level for the watch stands at $1.2333 in the near term. At $1.2767, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3033. If the price goes on to break the first support level at $1.1633, it is likely to go to the next support level at $1.1367. Now, if the price goes above the second support level, the third support stands at $1.0933.
Humacyte Inc (NASDAQ: HUMA) Key Stats
There are currently 155,119K shares outstanding in the company with a market cap of 184.59 million. Presently, the company’s annual sales total 0 K according to its annual income of -148,700 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -20,940 K.
